Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy

Drug News and Perspectives

Volumn 22, Issue 2, 2009, Pages 93-106

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; FC RECEPTOR; HERMES ANTIGEN; LAPATINIB; MICRORNA; MUCIN 4; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHROMOSOME 17; CHROMOSOME ANALYSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIMERIZATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; STRUCTURAL CHROMOSOME ABERRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOLOGICAL TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENES, ERBB-2; GENETIC TECHNIQUES; GUIDELINES AS TOPIC; HUMANS; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 65649133129     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.2.1334452     Document Type: Article

References (153)

1. Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I. and Weinberg, R.A. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312(5994): 513-6.
2. Ross, J.S., Fletcher, J.A., Bloom, K.J. et al. Targeted therapy in breast cancer. The HER-2/neu gene and protein. Mol Cell Proteomics 2004, 3(4): 379-98.
3. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1): 39-51.
4. Yarden, Y. and Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2): 127-37.
5. Tzahar, E., Waterman, H., Chen, X. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16(10): 5276-87.
6. Roskoski, R. Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004, 319(1): 1-11.
7. Karunagaran, D., Tzahar, E., Beerli, R.R. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996, 15(2): 254-64.
8. Kallioniemi, O., Kallioniemi, A., Kurisu, W. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992, 89(12): 5321-25.
9. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26(45): 6469-87.
10. Perou, C.M., Sorlie, T., Eisen, M.B. et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797): 747-52.
11. Slamon, D.J., Clark, G.M., Wong, S.G. et al. Human breast concer Correlation of relapse and survival with amplification of the Her2/neu oncogene. Science 1987, 235(4785): 177-82.
12. Masood, S. and Bui, M.M. Assessment of Her2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000, 30(3): 259-65.
13. Dittadi, R., Zancan, M., Perasole, A. et al. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001, 16(3): 255-261.
14. Simon, R., Nocito, A., Hubscher, T. et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001, 93(15): 1141-6.
15. Vincent-Salomon, A., Jouve, M., Genin, P. et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002, 94(8): 2169-73.
16. Xu, R., Perle, M.A., Inghirami, G., Chan, W., Delgado, Y. and Feiner, H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002, 15(2): 116-24.
17. Symmans, W.F., Liu, J., Knowles, D.M. and Inghirami, G. Breast cancer heterogeneity. evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995, 26(2): 210-6.
18. Bozzetti, C., Personeni, N., Nizzoti, R. et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003, 99(5): 310-5.
19. Tapia, C., Savic, S., Wagner, U. et al. HER2 gene status in primary breast cancers and matched distant metostases. Breast Cancer Res 2007, 9(3): R31.
20. Lower, E.E., Glass, E., Blau, R. and Harman, S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113(2): 301-6.
21. Eccles, S.A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6(4): 393-406.
22. Piccart, M., Lohrisch, C., Di Leo, A. et al. The predictive value of HER2 in breast cancer. Oncology 2001 61(Suppl. 2): 73-82.
23. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl. 2): 1-13.
24. Schnitt, S.J. and Jacobs, T.W. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001, 116(6): 806-10.
25. Hayes, D.F. and Thor, A.D. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002, 29(3): 231-45.
26. Masood, S. and Bui, M.M. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002, 59(2): 102-8.
27. Cuadros, M. and Villegas, R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009, 17(1): 1-7.
28. Press, M.F., Hung, G., Godolphin, W. et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemicol studies of oncogene expression. Cancer Res 1994, 54(10): 2771-7.
29. Paik, S., Bryant, J., Tan-Chiu, E. et al. Real-world performance of HER2 testing-national Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002, 94(11): 852-4.
30. Paik, S., Tan-chui, E., Bryan, J. et al. Successful quality assurance program for HER-2 testing in the NSAPB trial for Herceptin. Breast Cancer Res Treat 2002, 76(Suppl. 1): S31.
31. Dowsett, M., Hanby, A.M., Laing, R., Walker, R. and National HER2 Consultation Steering Group. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 2007, 60(6): 685-9.
32. Rhodes, A., Jasani, B., Anderson, E. et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formolin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 27 countries. Am J Clin Pathol 2002, 118(3): 408-17.
33. Wang, S., Saboorian, M.H., Frenkel, E.P. et al. Assessment of HER-2/ neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001, 116(4): 495-503.
34. Bloom, K.J., Torre-Bueno, J., Press, M., Gown, A., Bauer, K. and Harrington, D. Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis. Breast Cancer Res Treat 2000, 64: 99.
35. Vani, K., Sompuram, S.R., Fitzgibbons, P. and Bogen, S.A. National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. Arch Pathol Lab Med 2008, 132(2): 211-6.
36. Hicks, D.G. and Kulkarni, S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008, 129(2): 263-73.
37. Wang, S., Saboorian, M.H., Frenkel, E. et al. Laboratory assessment of the status of Her2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000, 53(5): 374-81.
38. Seelig, S. Fluorescence in situ hybridization versus immunohistochemistry: importance of clinical outcome. J Clin Oncot 1999, 17(11): 3690-2.
39. Lal, P., Salazar, P.A., Hudis, C.A. et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004, 121(5): 631-6.
40. Owens, M.A., Horten, B.C., Da Silva, M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5(1): 63-9.
41. Press, M.F., Sauter, G., Bernstein, L. et al. Diagnostic evaluation of HER-2 as a molecular target: on assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(18): 6598-6607.
42. Tubbs, R.R., Hicks, D.G., Cook, J. et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007, 16(4): 207-10.
43. Ross, J.S., Symmans, W.F., Pusztai, L. and Hortobagyi, G.N. Standardizing slide-based assays in breast cancer. hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 2007, 13(10): 2831-5.
44. Bartlett, J.M., Ibrahim, M., Jasani, B. et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol 2007, 60(7): 816-9.
45. Dendukuri, N., Khetani, K., McIsaac, M. and Brophy, J. Testing for HER2-positive breast cancer: A systematic review and cost-effectiveness analysis. CMAJ 2007, 176(10): 1429-34.
46. Carlson, R.W., Moench, S.J., Hammond, M.E. et al. HER2 testing in breast cancer. NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006, 4(Suppl. 3): S1-22.
47. Cuadros, M. and Villegas, R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol. 2009, 17(1): 1-7.
48. Perez, E.A. and Baweja, M. HER2-positive breast cancer. current treatment strategies. Cancer Invest 2008, 26(6): 545-52.
49. Hicks, D.G. and Kulkarni, S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2008, 132(6): 1008-15.
50. Lidgren, M., Wilking, N., Jonsson, B. et al. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008, 1: 1-11.
51. Tanner, M., Gancberg, D., Di Leo, A. et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157(5): 1467-72.
52. Zhao, J., Wu, R., Au, A. et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002, 15(6): 657-65.
53. Dietel, M., Ellis, I.O., Höfler, H. et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007, 451(1): 19-25.
54. Dandachi, N., Dietze, O. and Hauser-Kronberger, C. Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002, 82(8): 1007-14.
55. Hauser-Kronberger, C. and Dandachi, N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 2004, 35(6): 647-53.
56. Wixom, C.R., Albers, E.A. and Weidner, N. Her2 amplification: Correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl. Immunohistochem Mol Morphol 2004, 12(3): 248-51.
57. Li-Ning-T, E., Ronchetti, R., Torres-Cabata, C. et al. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol 2005, 13(4): 343-51.
58. Bilous, M., Morey, A., Armes, J. et al. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology 2006, 38(2): 120-4.
59. Hanna, W.M. and Kwok, K. Chromogenic in situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006, 19(4): 481-7.
60. van de Vijver, M., Bilous, M., Hanna, W. et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007, 9(5): R68.
61. Lambros, M.B., Natrajan, R. and Reis-Filho, J.S. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007, 38(8): 1105-22.
62. Di Palma, S., Collins, N., Faulkes, C. et al. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol 2007, 60(9): 1067-8.
63. Cho, E.Y., Choi, Y.L., Han, J.J. et al. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int 2008, 58(1): 17-25.
64. Pothos, A., Plastira, K., Plastiras, A. et al. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 2008, 41(3): 59-64.
65. Downs-Kelty, E., Yoder, B.J., Stoler, M. et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005, 29(9): 1221-7.
66. Beser, A.R., Tuzlali, S., Guzey, D. et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007, 13(3): 180-5.
67. Torrisi, R., Rotmensz, N., Bagnardi, V. et al. HER2 status in early breast cancer. relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007, 43(16): 2339-44.
68. Hyun, C.L., Lee, H.E., Kim, K.S. et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008, 61(3): 317-21.
69. Hofmann, M., Stoss, O., Gaiser, T. et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008, 61(1): 89-94.
70. Kaufman, P.A., Broadwater, G. and Lezon-Geyda, K. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trAstuzumab (T) efficacy in CALGB 9840, poclitaxel (P) with or without T in HER2+ and HER2- metastatic breast Cancer (MBC). J Clin Oncol 2007, 25:1009.
71. Livingston, R.B., Downey, L., Di Leo, A. et al. Evaluation of chromosome 17 (Chr-17) polysomy in HER2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib. J Clin Oncol 2008, 26: 1006.
72. Wolff, A.C., Hammond, M.E., Schwartz, J.N. et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007, 131(1): 18.
73. Tubbs, R.R., Pettay, J.D., Roche, P.C. et al. Discrepancies in clinical laboratory testing of eligibility for trAstuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001, 19(10): 2714-21.
74. Paik, S., Shak, S., Tang, G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negotive breast cancer. N Engl J Med 2004, 351(27): 2817-26.
75. Ross, J.S., Hatzis, C., Symmans, W.F. et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13(5): 477-93.
76. Bates, M.R, Desmedt, C., Sperinde, J. et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2-HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer. J Clin Oncol 2007, 25: 10557.
77. Toi, M., Sperinde, J., Huang, W. et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metostatic breast cancer. J Clin Oncol 2007, 25: 1025.
78. DiGiovanna, M.P. and Stern, D.F. Activation state-specific monoclonal antibody detects tyrosine phospharylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995, 55(9):1946-55.
79. Thor, A.D., Liu, S., Edgerton, S. et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000, 18(18): 3230-9.
80. Modi, S., DiGiovanna, M.P., Lu, Z. et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005, 23: 48.
81. Carney, W.P., Neumann, R., Lipton, A. et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004, 5(2): 105-16.
82. Fornier, M.N., Seidman, A.D., Schwartz, M.K. et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16(2): 234-9.
83. Kong, SY, Nam, B.H., Lee, K.S. et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52(8): 1510-5.
84. Ludovini, V., Gori, S., Colozza, M. et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19(5): 883-90.
85. Fehm, T., Jäger, W., Krämer, S. et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004, 24(3b): 1987-92.
86. Esteva, F.J., Cheli, C.D., Fritsche, H. et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005, 7(4): R436-43.
87. Cristofanilli, M., Budd, G.T., Ellis, M.J. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8): 781-91.
88. Riethdorf, S., Wikman, H. and Pantet, K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123(9): 1991-2006.
89. Wülfing, P., Borchard, J., Buerger, H. et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006, 12(6): 1715-20.
90. Tewes, M., Aktas, B., Welt, A. et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2008, Advance publication.
91. Ignatiadis, M., Kallergi, G., Ntoulia, M. et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 14(9): 2593-600.
92. Lang, J.E., Mosalpuria, K., Cristofanilli, M. et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009, 113(3): 501-7.
93. Smimov, D.A., Zweitzig, D.R., Foulk, B.W. et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65(12): 4993-7.
94. Pinzani, P., Salvadori, B., Simi, L. et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006, 37(6): 711-8.
95. Gervasoni, A., Monasterio Muñoz, R.M., Wengler, G.S. et al. Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett 2008, 263(2): 267-79.
96. Huston, J.S. and George, A.J. Engineered antibodies take center stage. Hum Antibodies 2001, 10(3-4): 127-42.
97. Hortobagyi, G.N. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001, 28(6, Suppl. 18): 43-7.
98. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for Metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11): 783-92.
99. HercepTest package Insert. Dako Corporation, Glostrup, Denmark.
100. Roche, P.C. and Ingle, J.N. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999, 17(1): 434.
101. Dybdal, N., Leiberman, C., Anderson, S. et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93(1): 3-11.
102. Vogel, C.L., Cobteigh, M.A., Tripathy, D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3): 719-26.
103. Seidman, A.D., Fornier, M.N., Esteva, F.J. et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001, 19(10): 2587-95.
104. Fornier, M., Risio, M., Van Poznak, C. and Seidman, A. HER-2 testing and correlation with efficacy in Trastuzumab therapy. Oncology 2003, 16(10): 1340-58.
105. Nichols, D.W., Wolff, D.J., Self, S. et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci 2002, 32(1): 3-11.
106. Yaziji, H. and Gown, A.M. Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome? Adv Anat Pathol 2002, 9(6): 338-44.
107. Press, M.F., Slamon, D.J. and Flom, K.J. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002, 20(14): 3095-105.
108. Romond, E.H., Perez, E.A., Bryant, J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16): 1673-84.
109. Paik, S., Kim, C. and Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358(13): 1409-11.
110. de Alava, E., Ocaña, A., Abad, M. et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007, 25(19): 2656-63.
111. Arnould, L., Arveux, P., Couturier, J. et al. Pothologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007, 13(21): 6404-9.
112. Han, H., Kim, J., Inn, S. et al. Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy. J Clin Oncol 2008, 26(May 20 Suppl): Abst 1053.
113. Baselga, J., Albanell, J., Molina, M.A. et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001, 28(5, Suppl. 16): 4-11.
114. Cho, H.S., Mason, K., Ramyar, K.X. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421(6924): 756-60.
115. Desjarlais, J.R., Lazar, G.A., Zhukovsky, E.A. et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007, 12(21-22): 898-910.
116. Strome, S.E., Sausville, E.A. and Mann, D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007, 12(9): 1084-95.
117. Sibéril, S., Dutertre, C.A., Fridman, W.H. et al. The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007, 62(1): 26-33.
118. Iannello, A. and Ahmad, A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005, 24(4): 487-99.
119. Musolino, A., Naldi, N., Bortesi, B. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26: 178.
120. Pandolfi, P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351(22): 2337-8.
121. Nagata, Y., Lan, K.H., Zhou, X. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2): 117-27.
122. Crowder, R.J., Lombardi, D.P. and Ellis, M.J. Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell 2004, 6(2): 103-4.
123. Park, B.H. and Davidson, N.E. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell 2007, 12(4): 297-9.
124. Berns, K., Horlings, H.M., Hennessy, B.T. et al. A functional genetic approach identifies the PI3K pathway as o major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4): 395-402.
125. Smith, K.L., Robbins, RD., Dawkins, H.J.S. et al. Detection of c-erbB-2 amplification in breast cancer by in situ hybridization. Breast 1993, 2: 234-8.
126. Kim, C., Bryant, J., Horne, Z. et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 2005, 94(56): Abst 46.
127. Gianni, L., Eiermann, W., Pusztai, L. et al. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). J Clin Oncol 2008, 26(Suppl.): Abst 504.
128. Nahta, R., Yuan, L.X., Zhang, B. et al. Insulin-like growth factor-1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65(23): 11118-28.
129. Shimizu, C., Hasegawa, T., Ando, M. et al. Relation between Insulin-like growth factor-1 receptor (ICF-1R) expression and the efficacy of trastuzumab (T) monotherapy for hormone-resistant HER2-postitive metastatic breast cancer (MBC). J Clin Oncol 2004, 22: 9578.
130. Köstler, W.J., Hudelist, G., Rabitsch, W. et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol 2006, 132(1): 9-18.
131. Lu, Y., Zi, X., Zhao, Y. et al. Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93(24): 1852-7.
132. Nahta, R., Yu, D., Hung, M.C. et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3(5): 269-80.
133. Molina, M.A., Saez, R., Ramsey, E.E. et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002, 8(2): 347-53.
134. Scaltriti, M., Rojo, F., Ocaña, A. et al. Expression of p9SHER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99(8): 628-38.
135. Hudelist, G., Kostler, W.J. and Attems, J. et al. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 2003, 89(6): 983-91.
136. Press, M.F., Bernstein, L., Sauter, G. et al. Topoisomerose II- gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. Breast Cancer Res Treat 2005, 94: S54.
137. Harris, L.N., You, F., Schnitt, S.J. et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13(4): 1198-207.
138. Palyi-Krekk, Z., Barok, M., Isola, J. et al. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007, 43(16): 2423-33.
139. Pegram, M.D. and Reese, D.M. Combined biological therapy of breast cancer using manoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002, 29(3 Suppl 11): 29-37.
140. Miller, T.E., Ghoshal, K., Ramaswamy, B. et al. MicroRNA-221/222 confers tomoxifen resistance in breast cancer by targeting p27(Kip1). J Biol Chem 2008, 283(44): 29897-903.
141. Medina, P.J. and Goodin, S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30(8): 1426-47.
142. Geyer, C.E., Forster, J., Lindquist, D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26): 2733-43.
143. Cameron, D., Casey, M., Press, M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomorker analyses. Breast Cancer Res Treat 2008, 112(3): 533-43.
144. Burstein, H.J., Stomiolo, A.M., Franco, S. et al. A phase II study of lapatinib monotherapy in chemotherapy- refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008, 19(6): 1068-74.
145. Lin, N.U., Carey, L.A., Liu, M.C. et al. Phase II trial of lapatinib for brain metastasis in patients with HER2+ breast cancer. J Clin Oncol 2006, 24: 503.
146. Finn, R.S., Gagnon, R., Di Leo, A. et al. Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study. J Clin Oncol 2008, 26(Suppl): Abstr 1017.
147. Salter, K.H., Acharya, C.R., Walters, K.S. et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008, 3(4): e1908.
148. Press, M.F., Finn, R.S., Di Leo, A. et al. Correlation of HER2 gene amplification, HER2 and ECFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 2008, 26: 1007.
149. Zhang, D., Pal, A., Bornmann, W.G. et al. Activity of lapatinib is independent of ECFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008, 7(7): 1846-50.
150. Martin, A.P., Miller, A., Emad, L. et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008, 7: 1846-50.
151. Nahta, R., Yuan, L.X., Du, Y. et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007, 6(2): 667-74.
152. Xia, W., Bacus, S., Hegde, P. et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006, 103(20): 7795-800.
153. Xia, W., Husain, I., Liu, L. et al. Lapatinib anti-tumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007, 67(3): 1170-5.